This comparative effectiveness study of immunocompromised patients and healthy controls in Switzerland examines differences in the magnitude and durability of neutralizing antibody responses against the original SARS-CoV-2 and several variants of concern according to the mRNA-1273 and BNT162b2 vaccines.
